Search - tctmd.com

Displaying 41 - 60 of 328

Sort: Relevancy | Date

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

News Conference News EACTS 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Michael O'Riordan

October 05, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

News Conference News ESC 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

August 26, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

News Conference News SCCT 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

July 31, 2023

Ticagrelor May Be an Option for Averting Brain Lesions During Carotid Stenting

News Conference News ESOC 2023

Ticagrelor May Be an Option for Averting Brain Lesions During Carotid Stenting

June 02, 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

News Conference News ESOC 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

May 25, 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

May 22, 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

News Conference News EuroPCR 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

May 18, 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

March 10, 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

News Conference News ISC 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

February 17, 2023

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.